Literature DB >> 21181371

Von Willebrand factor antigen and ADAMTS13 activity assay in pregnant women and severe preeclamptic patients.

Dandan Zhang1, Juan Xiao, Haoliang Huang, Juanjuan Chen, Tao Liu, Zongzhi Yin, Danping Gao, Qiong Liu, Jihui Ai, Suhua Chen.   

Abstract

The present study examined von Willebrand factor (vWF) levels and ADAMTS13 activity in pregnant and severe preeclamptic women in order to shed light on the prothrombotic state in severe preeclampsia. Thirty healthy women of childbearing age, 22 second trimester pregnant women, 30 third trimester pregnant women and 10 severe preeclamptic patients were recruited in this study. ADAMTS13 activity was determined by the FRETS-vWF73 assay and vWF antigen (vWF:Ag) levels by an enzyme-linked immunosorbent assay. The results showed that there were statistically significant differences in plasma vWF antigen levels between the severe preeclamptic and third trimester pregnant women, between third and second trimester pregnant women (P<0.05). The third trimester pregnant women had significantly lower plasma ADAMTS13 activity than second trimester pregnant women (P<0.05). Nevertheless, no significant differences in plasma ADAMTS13 activity were found between severe preeclamptic patients and the third trimester pregnant women (P>0.05). In conclusion, plasma ADAMTS13 activity is normal in severe preeclampsia despite the increased vWF:Ag levels. Prothrombotic state is involved in the pathogenesis of severe preeclampsia, as a result of endothelial injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21181371     DOI: 10.1007/s11596-010-0657-4

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  23 in total

1.  Fluorescence quenching: A tool for single-molecule protein-folding study.

Authors:  X Zhuang; T Ha; H D Kim; T Centner; S Labeit; S Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

2.  Creation of a recombinant peptide substrate for fluorescence resonance energy transfer-based protease assays.

Authors:  Lin Zhang; Heather L Lawson; Vallathucherry C Harish; Jason D Huff; Mary Ann Knovich; John Owen
Journal:  Anal Biochem       Date:  2006-07-05       Impact factor: 3.365

3.  Comparison of FRETS-VWF73 to full-length VWF as a substrate for ADAMTS13 activity measurement in human plasma samples.

Authors:  Reza Mahdian; Julie Rayes; Jean-Pierre Girma; Anne Houllier; Bernadette Obert; Dominique Meyer; Agnès Veyradier
Journal:  Thromb Haemost       Date:  2006-06       Impact factor: 5.249

4.  Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood.

Authors:  Roberta Donadelli; Jennifer N Orje; Cristina Capoferri; Giuseppe Remuzzi; Zaverio M Ruggeri
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

Review 5.  Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura.

Authors:  Miha Furlan; Bernhard Lämmle
Journal:  Semin Thromb Hemost       Date:  2002-04       Impact factor: 4.180

6.  Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies.

Authors:  L Oleksowicz; N Bhagwati; M DeLeon-Fernandez
Journal:  Cancer Res       Date:  1999-05-01       Impact factor: 12.701

7.  Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension.

Authors:  Harish Shankaran; Paschalis Alexandridis; Sriram Neelamegham
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

8.  Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.

Authors:  P M Mannucci; M T Canciani; I Forza; F Lussana; A Lattuada; E Rossi
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

9.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

10.  Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.

Authors:  Attila Molvarec; János Rigó; Tamás Bõze; Zoltán Derzsy; László Cervenak; Veronika Makó; Tímea Gombos; Miklós László Udvardy; Jolán Hársfalvi; Zoltán Prohászka
Journal:  Thromb Haemost       Date:  2009-02       Impact factor: 5.249

View more
  2 in total

Review 1.  Relationship between ABO blood group and pregnancy complications: a systematic literature analysis.

Authors:  Massimo Franchini; Carlo Mengoli; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2016-05-05       Impact factor: 3.443

2.  Low ADAMTS-13 predicts adverse outcomes in hospitalized patients with suspected heparin-induced thrombocytopenia.

Authors:  Meng Chan; Xinyang Zhao; X Long Zheng
Journal:  Res Pract Thromb Haemost       Date:  2021-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.